BCMA/CD19-targeted allogeneic CAR-T

DRUG2 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, The First Affiliated Hospital of Soochow University

Conditions

Multiple MylomaNewly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCTNewly Diagnosed Multiple Myeloma (NDMM)

Phase 1

RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma

Not yet recruitingNCT07114432

Tianjin Medical University Cancer Institute and HospitalNewly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT, Newly Diagnosed Multiple Myeloma (NDMM)

Start: 2025-08-31End: 2028-08-31Target: 19Updated: 2025-08-11

Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma

RecruitingNCT07652138

The First Affiliated Hospital of Soochow UniversityMultiple Myloma, Newly Diagnosed Multiple Myeloma (NDMM)

Start: 2025-07-30End: 2027-11-30Target: 18Updated: 2026-06-16